Entera Bio Taps Pfizer Veteran as Chairman Amid Critical Clinical Milestones
Event summary
- Entera Bio appointed Geno J. Germano, former Pfizer executive, as Chairman of the Board on February 4, 2026.
- Germano succeeds Gerald Lieberman, who is stepping down from the role.
- Entera plans to advance two oral PTH peptide programs into clinical testing within 2026.
- EB613 for osteoporosis and Long-Acting Oral PTH for hypoparathyroidism are key focus areas.
The big picture
Entera Bio's appointment of Geno J. Germano as Chairman underscores its strategic pivot toward late-stage clinical development and commercialization. Germano's extensive experience in scaling biopharmaceutical platforms at Pfizer aligns with Entera's goal of advancing its oral peptide therapies into critical clinical milestones. The move highlights the company's focus on transforming the treatment paradigm for osteoporosis and hypoparathyroidism through innovative, injection-free therapies.
What we're watching
- Clinical Execution
- Whether Entera can successfully advance its two oral PTH peptide programs into clinical testing within 2026.
- Strategic Leadership
- How Geno J. Germano's extensive experience in scaling biopharmaceutical platforms will impact Entera's late-stage development and commercialization efforts.
- Market Differentiation
- The pace at which Entera can establish its oral peptide therapies as a transformative standard of care in osteoporosis and hypoparathyroidism.
Related topics